The largest deal in Stem Cell research history is under way between two bio-techs who are prepared to invest 1.4 billion of their own money in the joint venture. Genzyme and Osiris are coordinating an effort to bring the next two stem cell drugs through the end stages of their trials and on to market– Prochymal and Chondrogen.
While this could be the beginning of a new wave of such partnerships, democrats might want to take note: these are private companies, investing their billions, and they are developing these new drugs with those other stem cells. You know, the ones that actually produce cures. The ones that come from Jeanne Shaheen, and the other so called adults in the government, not from harvested embryos.
(That’s right–Adult Stem cells)
This would bring the number of viable cures and treatments developed from adult stem cells to at least 80, with roughly 1200 more FDA approved clinical trials currently under way.
Embryonic stem cell research, by comparison, has yet to produce one single treatment or cure that I am aware of. The distinction is critical because our newly minted Senator elect, Jeanne Shaheen, has promised she’d try to pump 12 billion into the National Science Foundation specifically for embryonic stem cell research. Is she dumb enough to keep the promise? She certainly is.
